Influenza vaccines in immunosuppressed adults with cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Eliakim Raz, Noa ^a   Vinograd, Inbal ^b   Zalmanovici Trestioreanu, Anca ^a   Leibovici, Leonard ^a   Paul, Mical ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ADULT; ALL CAUSE MORTALITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; CLINICAL OUTCOME; DATA EXTRACTION; DATA SYNTHESIS; DISEASE ASSOCIATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA VACCINATION; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; SOLID MALIGNANT NEOPLASM; SYSTEMATIC REVIEW; THERAPY EFFECT; BONE MARROW TRANSPLANTATION; CASE CONTROL STUDY; CAUSE OF DEATH; COHORT ANALYSIS; HEMATOLOGIC DISEASE; IMMUNOLOGY; INFLUENZA, HUMAN; META ANALYSIS; MORTALITY; NEOPLASM; OBSERVATIONAL STUDY;

ADULT; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEOPLASMS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899467050     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008983.pub2     Document Type: Review

References (80)

1. Earle C C. Influenza vaccination in elderly patients with advanced colorectal cancer. Journal of Clinical Oncology 2003;21(6):1161-6.
2. Machado CM, Cardoso MRA, Da Rocha IF, Boas LSV, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplantation 2005;36:897-900.
3. Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. British Journal of Haematology 1997;97(2):504-10.
4. Vinograd I, Eliakim-Raz N, Farbman L, Baslo R, Taha A, Sakhnini A, et al.Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer 2013;16 SEP:Epub ahead of print. [: 10.1002/cncr.28351]
5. Adell C, Bayas JM, Vilella A, Perales M, Vidal J, Bertran MJ, et al.Post-transplantation vaccination of bone-marrow transplant recipients [Vacunacion de pacientes receptores de trasplante de progenitores hematopoyeticos]. Medicina Clinica Journal 2002;119(11):405-9.
6. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. British Journal of Cancer 1999;80:219-20.
7. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008;86(2):257-63.
8. Bedognetti D, Zoppoli G, Massucco C, Zupo S, Sertoli MR. Impaired humoral response to influenza vaccine and prolonged B memory cell depletion as a consequence of rituximab-based immunochemotherapy in non-hodgkin lymphoma patients. Journal of Immunotherapy 2009;32(9):992-3.
9. Bedognetti D, Zoppoli G, Zanardi E, Massucco C, Sertoli MR. Prolonged lack of humoral response to influenza vaccine associated with a persistent depletion of B memory cells in non-hodgkin's lymphoma patients treated with rituximab-containing immunochemotherapy. Clinical Immunology 2010;135:84.
10. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leukemia and Lymphoma 1999;32(3-4):369-74.
11. Brydak LB, Guzy J, Starzyk J, Machala M, Gozdz SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001;9(1):65-8.
12. Brydak LB, Machala M, Centkowski P, Warzocha K, Bilinski P. Humoral response to hemagglutinin components of influenza vaccine inpatients with non-Hodgkin malignant lymphoma. Vaccine 2006;24:6620-23.
13. Bucalossi A, Marotta G, Galieni P, Bigazzi C, Valenzin PE, Dispensa E. Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematologica 1995;93(1):56.
14. Centkowski P, Brydak L, Machala M, Kalinka-Warzocha E, Blasinska-Morawiec M, Federowicz I, et al.Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. Journal of Clinical Immunology 2007;27(3):339-46.
15. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M. Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. Journal of Clinical Oncology 2009;27:e20575.
16. De Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al.Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011;96(2):307-14.
17. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al.Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11(1):1-5.
18. Feery BJ, Sullivan JR, Hurley TH, Evered MG. Immunization with influenza vaccine in patients with haematological malignant disease. Medical Journal of Australia 1977;1:292-4.
19. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer 1978;42:2244-7.
20. Gribabis DA, Panayiotidis P, Boussiotis VA, Hannoun C, Pangalis GA. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematologica 1994;91(3):115-8.
21. Hodges GR, Davis JW, Lewis HD Jr, Whittier FC Jr, Siegel CD, Chinn TD, et al.Response to influenza A vaccine among high-risk patients. Southern Medical Journal 1979;72(1):29-32.
22. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alvea EP, et al.Seroprotectivetiters against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biological Blood MarrowTransplant 2011;17(3):434-8.
23. Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, et al.Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. Journal of Medical Virology 2009;81(4):722-7.
24. Lachenal F, Sebban C, Duruisseaux M, Biron P, Blay JY, Ghesquières H. Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. Bulletin du Cancer 2010;97(4):E33-6.
25. Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes and Control 2009;20(5):517-23.
26. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British Journal of Haematology 2005;130(1):96-8.
27. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. European Journal of Clinical Microbiology & Infectious Diseases 1993;12(10):778-82.
28. Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, et al.Efficacy of the influenza vaccine in patients with malignant lymphoma. Clinical Medicine and Research 2005;3(4):214-20.
29. Mulder SF, Jacobs JFM, Olde Nordkamp MAM, Kremer IK, Mulders PFA. Immunological response to influenza vaccine in cancer patients undergoing treatment with sunitinib or sorafenib. European Journal of Cancer 2009;7:116.
30. Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, et al.Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Medical Oncology 2002;19(2):71-8.
31. Ortbals DW, Liebhaber H, Presant CA, Van Amburg AL 3rd, Lee JY. Influenza immunization of adult patients with malignant diseases. Annals of Internal Medicine 1977;87(5):552-7.
32. Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, et al.Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology 2011;67(1):111-5.
33. Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. European Journal of Haematology 2003;70(4):225-30.
34. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, et al.Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. British Journal of Cancer 2000;82(7):1261-5.
35. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, et al.Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. Journal of Infectious Diseases 2006;194(10):1394-7.
36. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43(1):25-30.
37. Shildt RA, Luedke DW, Kasai G, El-Beheri S, Laham MN. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979;44(5):1629-35.
38. Spies CD, Kip M, Lau A, Sander M, Breuer JP, Meyerhoefer J, et al.Influence of vaccination and surgery on HLA-DR expression in patients with upper aerodigestive tract cancer. Journal of International Medical Research 2008;36:296-307.
39. Spitaleri G, Delmonte A, Toffalorio F, De Pas TM, Gregorc V. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. Journal of Thoracic Oncology 2010;5(5):752-4.
40. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Canadian Medical Association Journal 1978;119(7):733-8.
41. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. Journal of Clinical Experimental Hematopathology 2009;49(1):9-13.
42. Van der Velden AM, Mulder AH, Hartkamp A, Diepersloot RJ, Van Velzen-Blad H, Biesma DH. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. European Journal of Internal Medicine 2001;12(5):420-4.
43. Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao YY, et al.A prospective study of the immunogenicity of inactivated influenza A (H1N1) 2009 monovalent vaccine in patients who have solid or hematologic malignancies. 48th Annual Meeting of the Infectious Diseases Society of America, 21-24 October 2010; Vancouver, Canada. 2010; Vol. Abstract 5075, posterLB-5013.
44. Yalçin SS, Kondolot M, Albayrak N, Altaş AB, Karacan Y, Kuşkonmaz B, et al.Serological response to influenza vaccine after hematopoetic stem cell transplantation. Annals of Hematology 2010;89(9):913-8.
45. Alistair R, Gavin M, Christopher S, Peter H. Influenza vaccination and chemotherapy: a shot in the dark?. Supportive Care in Cancer 2002;10:462-65.
46. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Medicine 2008;9(1):57-61.
47. Angelo SJ, Marshall PS, Chrissoheris MP, Chaves AM. Clinical characteristics associated with poor outcome in patients acutely infected with Influenza A. Connecticut Medicine 2004;68:199-205.
48. Arrowood JR, Hayney MS. Immunization recommendations for adults with cancer. Annals of Pharmacotherapy 2002;36:1219-29.
49. Centers for Disease Control and Prevention. Cancer prevention and control. Available from: http://www.cdc.gov/cancer/flu/ (accessed 12th December 2010).
50. Centers for Disease Control and Prevention. Preventing infections in cancer patients. Available from:http://www.cdc.gov/cancer/flu/#4 (Accessed 30th November 2012).
51. Centers for Disease Control and Prevention. Flu Activity & Surveillance. Available from: http://www.cdc.gov/flu/weekly/fluactivity.htm (accessed 12th December 2010).
52. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. Morbidity and Mortality Weekly Report (MMWR) 2010 Aug 27;59(33):1057-62.
53. Centers for Disease Control and Prevention. Seasonal Influenza. Available from: http://www.cdc.gov/flu/professionals/vaccination/effectivenessqa.htm (accessed 3oth November 2009).
54. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al.Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85(5):278-87.
55. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
56. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005;104:618-28.
57. De Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of Medical Virology 2000;61(1):94-9.
58. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Supportive Care in Cancer 1995;3(3):198-202.
59. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al.Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 2009;58:1-52.
60. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. New England Journal of Medicine 2008;359:2579-85.
61. Goossen GM, Kremer LCM, Van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006484]
62. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003;32(1):73-77.
63. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta- analysis. Statistics in Medicine 2002;21(11):1539-58.
64. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
65. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clinical Infectious Diseases 2009;48(6):772-86.
66. Kamps BS, Hoffmann C, Preiser W. Influenza report. http://www.influenzareport.com/influenzareport.pdf (accessed 31st December 2006).
67. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infectious Diseases 2009;9:493-504.
68. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biology of Blood and Marrow Transplantation 2001;7:5S-7S.
69. Machado CM, Boas LS, Mendes AV, Santos MF, Da Rocha IF, Sturaro D, et al.Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplantation 2003;31(8):695-700.
70. Melcher L. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clinical Oncology (Royal College of Radiologists) 2005;17(1):12-15.
71. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clinical Infectious Diseases 2004;39(9):1300-06.
72. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al.Newcastle Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed June 2010).
73. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clinical Microbiology Reviews 1998;11(1):1-26.
74. Redelman-Sidi G, Sepkowitz KA, Huang CK, Park S, Stiles J, Eagan J, et al.2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. Journal of Infection 2010;60(4):257-63.
75. Scottish Intercollegiate Guideline Network. Search Filters, Methodology. Available from: http://www.sign.ac.uk/methodology/filters.html (last modified 16 June 2010; accessed 21st June 2010).
76. Dolin, R. Clinical manifestations and diagnosis of seasonal influenza in adults. www.uptodate.com (accessed 31st December 2010).
77. World Health Organization. Influenza (Seasonal). Fact sheet N°211; 2009. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 31st December 2010).
78. World Health Organization. Global influenza surveillance 2009. Available from: http://www.who.int/csr/disease/influenza/influenzanetwork/en/index.html (accessed 31st December 2010).
79. Wiselka M. Influenza: diagnosis, management, and prophylaxis. BMJ 1994;308(6940):1341-45.
80. Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, et al.Influenza among hospitalized adults with leukemia. Clinical Infectious Diseases 1997;24:1095-99.